Enlivex Therapeutics Ltd. (ENLV)

Market Cap	78.12M
Revenue (ttm)	n/a
Net Income (ttm)	-26.30M
Shares Out	18.38M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,345
Open	4.36
Previous Close	4.14
Day's Range	4.14 - 4.42
52-Week Range	3.65 - 9.85
Beta	0.41
Analysts	Buy
Price Target	15.30 (+260.0%)
Earnings Date	Aug 22, 2022

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

• Industry: Software
• IPO Date: Dec 12, 1995
• CEO: Dror Mevorach
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ENLV stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 260.00% from the latest price.

Price Target

$15.3

(260.00% upside)

Analyst Consensus: Buy

Stock Forecasts